Pharma & Healthcare

Global Immune Checkpoint Inhibitors for Cancer Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Immune Checkpoint Inhibitors for Cancer market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Bristol Myers Squibb
Merck
Regeneron Pharmaceuticals
Roche
AstraZeneca
Innovent Biologics
Zydus
Pfizer
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Squamous Cell Skin Cancer
Non-small Cell Lung Cancer
Melanoma
Gastric Cancer
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Immune Checkpoint Inhibitors for Cancer study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Immune Checkpoint Inhibitors for Cancer: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Immune Checkpoint Inhibitors for Cancer Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Market Segmentation by Application
1.3.1 Global Immune Checkpoint Inhibitors for Cancer Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Squamous Cell Skin Cancer
1.3.3 Non-small Cell Lung Cancer
1.3.4 Melanoma
1.3.5 Gastric Cancer
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Immune Checkpoint Inhibitors for Cancer Revenue Estimates and Forecasts 2020-2031
2.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Immune Checkpoint Inhibitors for Cancer Sales Estimates and Forecasts 2020-2031
2.4 Global Immune Checkpoint Inhibitors for Cancer Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Immune Checkpoint Inhibitors for Cancer Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 PD-1 Inhibitors Market Size by Manufacturers
3.5.2 PD-L1 Inhibitors Market Size by Manufacturers
3.5.3 CTLA-4 Inhibitors Market Size by Manufacturers
3.6 Global Immune Checkpoint Inhibitors for Cancer Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Immune Checkpoint Inhibitors for Cancer Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Immune Checkpoint Inhibitors for Cancer Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
6.4 North America Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Immune Checkpoint Inhibitors for Cancer Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
7.4 Europe Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Immune Checkpoint Inhibitors for Cancer Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Immune Checkpoint Inhibitors for Cancer Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
9.4 Central and South America Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Immune Checkpoint Inhibitors for Cancer Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Immune Checkpoint Inhibitors for Cancer Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Corporation Information
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.1.4 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales by Product in 2024
11.1.6 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales by Application in 2024
11.1.7 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales by Geographic Area in 2024
11.1.8 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer SWOT Analysis
11.1.9 Bristol Myers Squibb Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Business Overview
11.2.3 Merck Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.2.4 Merck Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Merck Immune Checkpoint Inhibitors for Cancer Sales by Product in 2024
11.2.6 Merck Immune Checkpoint Inhibitors for Cancer Sales by Application in 2024
11.2.7 Merck Immune Checkpoint Inhibitors for Cancer Sales by Geographic Area in 2024
11.2.8 Merck Immune Checkpoint Inhibitors for Cancer SWOT Analysis
11.2.9 Merck Recent Developments
11.3 Regeneron Pharmaceuticals
11.3.1 Regeneron Pharmaceuticals Corporation Information
11.3.2 Regeneron Pharmaceuticals Business Overview
11.3.3 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.3.4 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales by Product in 2024
11.3.6 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales by Application in 2024
11.3.7 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales by Geographic Area in 2024
11.3.8 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer SWOT Analysis
11.3.9 Regeneron Pharmaceuticals Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Business Overview
11.4.3 Roche Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.4.4 Roche Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Roche Immune Checkpoint Inhibitors for Cancer Sales by Product in 2024
11.4.6 Roche Immune Checkpoint Inhibitors for Cancer Sales by Application in 2024
11.4.7 Roche Immune Checkpoint Inhibitors for Cancer Sales by Geographic Area in 2024
11.4.8 Roche Immune Checkpoint Inhibitors for Cancer SWOT Analysis
11.4.9 Roche Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.5.4 AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales by Product in 2024
11.5.6 AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales by Application in 2024
11.5.7 AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales by Geographic Area in 2024
11.5.8 AstraZeneca Immune Checkpoint Inhibitors for Cancer SWOT Analysis
11.5.9 AstraZeneca Recent Developments
11.6 Innovent Biologics
11.6.1 Innovent Biologics Corporation Information
11.6.2 Innovent Biologics Business Overview
11.6.3 Innovent Biologics Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.6.4 Innovent Biologics Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Innovent Biologics Recent Developments
11.7 Zydus
11.7.1 Zydus Corporation Information
11.7.2 Zydus Business Overview
11.7.3 Zydus Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.7.4 Zydus Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Zydus Recent Developments
11.8 Pfizer
11.8.1 Pfizer Corporation Information
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Immune Checkpoint Inhibitors for Cancer Product Models, Descriptions and Specifications
11.8.4 Pfizer Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Pfizer Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Immune Checkpoint Inhibitors for Cancer Industry Chain
12.2 Immune Checkpoint Inhibitors for Cancer Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Immune Checkpoint Inhibitors for Cancer Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Immune Checkpoint Inhibitors for Cancer Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Immune Checkpoint Inhibitors for Cancer Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Immune Checkpoint Inhibitors for Cancer Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Immune Checkpoint Inhibitors for Cancer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Immune Checkpoint Inhibitors for Cancer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Immune Checkpoint Inhibitors for Cancer Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Immune Checkpoint Inhibitors for Cancer Sales by Region (2020-2025) & (K Units)
Table 8. Global Immune Checkpoint Inhibitors for Cancer Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Immune Checkpoint Inhibitors for Cancer Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Immune Checkpoint Inhibitors for Cancer Sales Share by Manufacturers (2020-2025)
Table 12. Global Immune Checkpoint Inhibitors for Cancer Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Immune Checkpoint Inhibitors for Cancer by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors for Cancer as of 2024)
Table 16. Global Immune Checkpoint Inhibitors for Cancer Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Immune Checkpoint Inhibitors for Cancer Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Immune Checkpoint Inhibitors for Cancer Manufacturing Base and Headquarters
Table 19. Global Immune Checkpoint Inhibitors for Cancer Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2020-2025) & (K Units)
Table 23. Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2026-2031) & (K Units)
Table 24. Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Immune Checkpoint Inhibitors for Cancer ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2020-2025) & (K Units)
Table 29. Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2026-2031) & (K Units)
Table 30. Immune Checkpoint Inhibitors for Cancer High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Immune Checkpoint Inhibitors for Cancer ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Immune Checkpoint Inhibitors for Cancer Growth Accelerators and Market Barriers
Table 37. North America Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Immune Checkpoint Inhibitors for Cancer Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Immune Checkpoint Inhibitors for Cancer Growth Accelerators and Market Barriers
Table 40. Europe Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Immune Checkpoint Inhibitors for Cancer Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Growth Accelerators and Market Barriers
Table 45. Southeast Asia Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Immune Checkpoint Inhibitors for Cancer Investment Opportunities and Key Challenges
Table 47. Central and South America Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Bristol Myers Squibb Corporation Information
Table 51. Bristol Myers Squibb Description and Major Businesses
Table 52. Bristol Myers Squibb Product Models, Descriptions and Specifications
Table 53. Bristol Myers Squibb Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Bristol Myers Squibb Sales Value Proportion by Product in 2024
Table 55. Bristol Myers Squibb Sales Value Proportion by Application in 2024
Table 56. Bristol Myers Squibb Sales Value Proportion by Geographic Area in 2024
Table 57. Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer SWOT Analysis
Table 58. Bristol Myers Squibb Recent Developments
Table 59. Merck Corporation Information
Table 60. Merck Description and Major Businesses
Table 61. Merck Product Models, Descriptions and Specifications
Table 62. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Merck Sales Value Proportion by Product in 2024
Table 64. Merck Sales Value Proportion by Application in 2024
Table 65. Merck Sales Value Proportion by Geographic Area in 2024
Table 66. Merck Immune Checkpoint Inhibitors for Cancer SWOT Analysis
Table 67. Merck Recent Developments
Table 68. Regeneron Pharmaceuticals Corporation Information
Table 69. Regeneron Pharmaceuticals Description and Major Businesses
Table 70. Regeneron Pharmaceuticals Product Models, Descriptions and Specifications
Table 71. Regeneron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Regeneron Pharmaceuticals Sales Value Proportion by Product in 2024
Table 73. Regeneron Pharmaceuticals Sales Value Proportion by Application in 2024
Table 74. Regeneron Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 75. Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer SWOT Analysis
Table 76. Regeneron Pharmaceuticals Recent Developments
Table 77. Roche Corporation Information
Table 78. Roche Description and Major Businesses
Table 79. Roche Product Models, Descriptions and Specifications
Table 80. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Roche Sales Value Proportion by Product in 2024
Table 82. Roche Sales Value Proportion by Application in 2024
Table 83. Roche Sales Value Proportion by Geographic Area in 2024
Table 84. Roche Immune Checkpoint Inhibitors for Cancer SWOT Analysis
Table 85. Roche Recent Developments
Table 86. AstraZeneca Corporation Information
Table 87. AstraZeneca Description and Major Businesses
Table 88. AstraZeneca Product Models, Descriptions and Specifications
Table 89. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. AstraZeneca Sales Value Proportion by Product in 2024
Table 91. AstraZeneca Sales Value Proportion by Application in 2024
Table 92. AstraZeneca Sales Value Proportion by Geographic Area in 2024
Table 93. AstraZeneca Immune Checkpoint Inhibitors for Cancer SWOT Analysis
Table 94. AstraZeneca Recent Developments
Table 95. Innovent Biologics Corporation Information
Table 96. Innovent Biologics Description and Major Businesses
Table 97. Innovent Biologics Product Models, Descriptions and Specifications
Table 98. Innovent Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Innovent Biologics Recent Developments
Table 100. Zydus Corporation Information
Table 101. Zydus Description and Major Businesses
Table 102. Zydus Product Models, Descriptions and Specifications
Table 103. Zydus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Zydus Recent Developments
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Major Businesses
Table 107. Pfizer Product Models, Descriptions and Specifications
Table 108. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Pfizer Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources


List of Figures
Figure 1. Immune Checkpoint Inhibitors for Cancer Product Picture
Figure 2. Global Immune Checkpoint Inhibitors for Cancer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. PD-1 Inhibitors Product Picture
Figure 4. PD-L1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. Global Immune Checkpoint Inhibitors for Cancer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Squamous Cell Skin Cancer
Figure 8. Non-small Cell Lung Cancer
Figure 9. Melanoma
Figure 10. Gastric Cancer
Figure 11. Other
Figure 12. Immune Checkpoint Inhibitors for Cancer Report Years Considered
Figure 13. Global Immune Checkpoint Inhibitors for Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 15. Global Immune Checkpoint Inhibitors for Cancer Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region (2020-2031)
Figure 17. Global Immune Checkpoint Inhibitors for Cancer Sales (2020-2031) & (K Units)
Figure 18. Global Immune Checkpoint Inhibitors for Cancer Sales (CAGR) by Region (2020-2031) (K Units)
Figure 19. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Region (2020-2031)
Figure 20. Top 5 and Top 10 Manufacturers Immune Checkpoint Inhibitors for Cancer Sales Volume Market Share in 2024
Figure 21. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share Ranking (2024)
Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 23. PD-1 Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 24. PD-L1 Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 25. CTLA-4 Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 26. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2020-2031)
Figure 27. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2020-2031)
Figure 28. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2020-2031)
Figure 29. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2020-2031)
Figure 30. North America Immune Checkpoint Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 31. North America Immune Checkpoint Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 32. North America Top 5 Manufacturers Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 33. North America Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Type (2020- 2031)
Figure 34. North America Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 35. North America Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 36. North America Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 37. US Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 38. Canada Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 39. Mexico Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 40. Europe Immune Checkpoint Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 41. Europe Immune Checkpoint Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Europe Top 5 Manufacturers Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 43. Europe Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Type (2020-2031)
Figure 44. Europe Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020-2031)
Figure 45. Europe Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 46. Europe Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 47. Germany Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 48. France Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 49. U.K. Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 50. Italy Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 51. Russia Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 53. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Asia-Pacific Top 8 Manufacturers Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 55. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Type (2020- 2031)
Figure 56. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 57. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 58. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 59. Indonesia Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 60. Japan Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 61. South Korea Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 62. China Taiwan Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 63. India Immune Checkpoint Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 64. Central and South America Immune Checkpoint Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 65. Central and South America Immune Checkpoint Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 66. Central and South America Top 5 Manufacturers Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 67. Central and South America Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Type (2021-2031)
Figure 68. Central and South America Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020-2031)
Figure 69. Central and South America Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 70. Central and South America Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 71. Brazil Immune Checkpoint Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 72. Argentina Immune Checkpoint Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 73. Middle East, and Africa Immune Checkpoint Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 74. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 75. Middle East and Africa Top 5 Manufacturers Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 76. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Type (2021-2031)
Figure 77. South America Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020-2031)
Figure 78. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 79. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 80. GCC Countries Immune Checkpoint Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 81. Turkey Immune Checkpoint Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 82. Egypt Immune Checkpoint Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 83. South Africa Immune Checkpoint Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 84. Immune Checkpoint Inhibitors for Cancer Industry Chain Mapping
Figure 85. Regional Immune Checkpoint Inhibitors for Cancer Manufacturing Base Distribution (%)
Figure 86. Global Immune Checkpoint Inhibitors for Cancer Production Market Share by Region (2020-2031)
Figure 87. Immune Checkpoint Inhibitors for Cancer Production Process
Figure 88. Regional Immune Checkpoint Inhibitors for Cancer Production Cost Structure
Figure 89. Channels of Distribution (Direct Vs Distribution)
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies